AB
MNPR icon

Amalgamated Bank’s Monopar Therapeutics MNPR Stock Holding History

Amalgamated Bank’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144
Closed -$9K – 2353
2025
Q4 		$9K Buy
144
+5
+4% +$409 ﹤0.01% 2475
2025
Q3 		$11K Hold
139
– – ﹤0.01% 2423
2025
Q2 		$5K Buy
+139
New +$5.05K ﹤0.01% 2763

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Amalgamated Bank's MNPR Position: Q1 2026 in Review

Amalgamated Bank sold out of Monopar Therapeutics (MNPR) in Q1 2026, closing a stake of 144 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in MNPR in Q2 2025 and held it in 3 quarters. The position peaked at $11K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Amalgamated Bank reported no remaining Monopar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 144 Monopar Therapeutics shares in Q1 2026, an estimated $9K.
  • Amalgamated Bank first reported a position in Monopar Therapeutics in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Monopar Therapeutics position peaked at $11K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.